Glycated albumin refers to albumin that are bonded to glucose. Albumin is present in blood and body fluids organs, and functions to maintain the shape of cell and helps in the distribution of hormones, nutrients, and some drugs in the body. Glycated albumin has been described as novel biomarkers for the detection and management of diabetes. It has also gained importance in glycemic monitoring for diabetes mellitus over the past few decades.
Increasing approval of novel glycated albumin products by key players in the market is expected to drive global glycated albumin kits/assays market growth in the near future. For instance, in 2017, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance to Japan-based Asahi Kasei Pharma Corporation for its new Lucica Glycated Albumin-L, an in vitro diagnostic assay kit for glycated albumin (GA-L).
Furthermore, increasing prevalence of diabetes is expected to increase the demand for glycated albumin products, which can be used for the diagnosis/ detection of different types of diabetes such as type 1, and type 2 diabetes. For instance, according to the data published by the American Diabetes Associations in 2015, diabetes is the 7th leading cause of death in the U.S., where around 30.3 million people in the U.S. are suffering from diabetes. Among these, around 193,000 people in the U.S. below the age of 20 are suffering from diabetes.
- This report provides in-depth analysis of glycated albumin market and provides market size (US$ Million) and cumulative annual growth rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global glycated albumin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Lifespan Biosciences, Biomatik Corporation, Abbexa Ltd., G Biosciences, DRG International, Inc., Amsbio LLC, Signalway Antibody LLC, United States Biological, Diazyme Laboratories, Abnova Corporation, Maccura Biotechnology Co. Ltd., Exocell Inc., Biorbyt Ltd., and Epinex Diagnostics Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global glycated albumin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the glycated albumin market
-
- Human Glycated Albumin
- Animal Glycated Albumin
-
- Diagnosis
- Prediabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Research
-
- Hospitals/Clinics
- Diagnostic Centers
- Research Institutes
- Others
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Lifespan Biosciences
- Biomatik Corporation
- Abbexa Ltd.
- G Biosciences
- DRG International, Inc.
- Amsbio LLC
- Signalway Antibody LLC
- United States Biological
- Diazyme Laboratories,
- Abnova Corporation
- Maccura Biotechnology Co. Ltd.
- Exocell Inc.
- Biorbyt Ltd.
- Epinex Diagnostics Inc.
